Mode
Text Size
Log in / Sign up

Low-frequency rTMS and cathodal tDCS provide consistent seizure reductions in drug-resistant epilepsyNon-invasive Neuromodulation Shows Promise for Drug-Resistant Epilepsy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider low-frequency rTMS and cathodal tDCS for consistent seizure reduction in drug-resistant epilepsy.

This narrative review synthesizes evidence regarding non-invasive neuromodulation (NIN) for patients with drug-resistant epilepsy (DRE). The review evaluates several modalities, including repetitive transcranial magnetic stimulation (rTMS), transcranial electrical stimulation (tDCS), transcutaneous vagus nerve stimulation, trigeminal nerve stimulation, and transcranial focused ultrasound. The primary focus is on the reduction of seizure frequency and interictal epileptiform discharges.

The authors conclude that low-frequency rTMS and cathodal tDCS provide the most consistent reductions in seizure frequency and interictal epileptiform discharges. Transcutaneous vagus nerve stimulation is noted for encouraging results and an excellent safety profile. Conversely, focused ultrasound, trigeminal nerve stimulation, and temporal interference stimulation are currently considered investigational and require further clinical validation.

Several limitations impact the certainty of these findings, including heterogeneous stimulation protocols, small study populations, and variable outcome measures. Despite these limitations, the authors suggest that NIN is an increasingly relevant component of personalized epilepsy care. It represents a promising avenue for expanding therapeutic options for patients with drug-resistant epilepsy. Clinical application should be tempered by the fact that several modalities are still in the investigational phase.

How this fits prior evidence

This narrative review addresses a gap in the management of drug-resistant epilepsy by evaluating non-invasive neuromodulation. While prior coverage has addressed supportive care such as exercise for neuroprotective benefits and behavioral interventions for depression, this review focuses on the direct management of seizure frequency. It provides a framework for integrating NIN into personalized care for patients who do not respond to standard therapies.

This review looked at non-invasive neuromodulation, which are ways to stimulate the nervous system without surgery. The review focused on patients with drug-resistant epilepsy, a condition where seizures are not well-controlled by standard medications. Several methods were reviewed, including repetitive transcranial magnetic stimulation (rTMS) and transcranial electrical stimulation (tDCS).

Researchers found that low-frequency rTMS and cathodal tDCS provided the most consistent reductions in seizure frequency and electrical activity between seizures. Another method, transcutaneous vagus nerve stimulation, showed encouraging results and was noted for having an excellent safety profile. Other methods, such as focused ultrasound and trigeminal nerve stimulation, are still considered investigational and need more testing.

Because the available studies were small and used different methods, the evidence is not yet definitive. These treatments are becoming more relevant for personalized care. Patients should talk to their doctors to see if these emerging options are appropriate for their specific treatment plan.

What this means for you:
Certain non-invasive brain stimulations show promise for reducing seizures in drug-resistant epilepsy.

Common questions

What are the most consistent treatments for drug-resistant epilepsy?

The review found that low-frequency rTMS and cathodal tDCS provided the most consistent reductions in seizure frequency and interictal epileptiform discharges. These methods are currently among the more consistent options for patients whose seizures are not controlled by standard medications.

Is transcutaneous vagus nerve stimulation safe?

Transcutaneous vagus nerve stimulation was reported to have an excellent safety profile in the reviewed data. While it showed encouraging results for managing seizures, you should discuss the specific risks and benefits with your doctor.

Are all brain stimulation methods equally proven?

No, some methods are still being studied. While rTMS and tDCS showed consistent results, focused ultrasound, trigeminal nerve stimulation, and temporal interference stimulation are still investigational and require more clinical validation before they can be widely used.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Drug-resistant epilepsy (DRE) affects nearly one-third of people with epilepsy and remains a major cause of disability despite continued advances in antiseizure medications and surgical therapies. For patients who are not candidates for resective surgery or invasive neuromodulation, non-invasive neuromodulation (NIN) has emerged as a promising strategy to modulate epileptic networks while avoiding the risks associated with implanted devices. This structured narrative review examines current evidence across the principal NIN modalities, including repetitive transcranial magnetic stimulation (rTMS), transcranial electrical stimulation (transcranial direct current (tDCS), alternating current, and temporal interference stimulation), transcutaneous vagus nerve stimulation, trigeminal nerve stimulation, and transcranial focused ultrasound. We integrate current knowledge on mechanisms of action, clinical efficacy, safety, and practical considerations while highlighting recent advances that may shape future clinical implementation. Available evidence indicates that low-frequency rTMS and cathodal tDCS provide the most consistent reductions in seizure frequency and interictal epileptiform discharges, particularly in focal DRE. Transcutaneous vagus nerve stimulation has shown encouraging results with an excellent safety profile, whereas focused ultrasound, trigeminal nerve stimulation, and temporal interference stimulation remain investigational and require further clinical validation. Across modalities, interpretation of current evidence is limited by heterogeneous stimulation protocols, small study populations, and variable outcome measures. Emerging approaches, including individualized targeting, connectome-guided stimulation, computational modeling, neurophysiological biomarkers, and adaptive closed-loop neuromodulation, are expected to improve treatment precision and patient selection. Although high-quality multicenter randomized trials remain necessary, current evidence supports NIN as an increasingly relevant component of personalized epilepsy care and a promising avenue for expanding therapeutic options in DRE.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.